Simulations Plus (NASDAQ:SLP) Updates FY25 Earnings Guidance

Simulations Plus (NASDAQ:SLP - Get Free Report) issued an update on its FY25 earnings guidance on Tuesday morning. The company provided EPS guidance of $1.07-$1.20 for the period, compared to the consensus EPS estimate of $1.01. The company issued revenue guidance of $90-$93 million, compared to the consensus revenue estimate of $90.71 million. Simulations Plus also updated its FY 2025 guidance to 1.070-1.200 EPS.

Simulations Plus Stock Up 4.4 %

Shares of Simulations Plus stock traded up $1.29 during midday trading on Tuesday, hitting $30.39. The company's stock had a trading volume of 523,489 shares, compared to its average volume of 317,796. Simulations Plus has a 1-year low of $27.07 and a 1-year high of $51.22. The firm has a market capitalization of $610.38 million, a P/E ratio of 62.02 and a beta of 0.80. The stock has a 50-day simple moving average of $29.78 and a 200-day simple moving average of $34.16.

Simulations Plus (NASDAQ:SLP - Get Free Report) last released its quarterly earnings data on Wednesday, October 23rd. The technology company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.02. Simulations Plus had a net margin of 14.15% and a return on equity of 6.16%. The firm had revenue of $18.70 million for the quarter, compared to analyst estimates of $19.73 million. During the same quarter in the prior year, the business earned $0.18 EPS. The company's revenue for the quarter was up 19.9% compared to the same quarter last year. As a group, sell-side analysts predict that Simulations Plus will post 1.1 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on SLP shares. StockNews.com downgraded Simulations Plus from a "hold" rating to a "sell" rating in a report on Monday, November 4th. William Blair reaffirmed an "outperform" rating on shares of Simulations Plus in a report on Wednesday, November 6th. BTIG Research dropped their target price on shares of Simulations Plus from $60.00 to $50.00 and set a "buy" rating on the stock in a report on Thursday, October 24th. Finally, Stephens began coverage on shares of Simulations Plus in a report on Friday, November 15th. They set an "overweight" rating and a $39.00 price target for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $51.40.

Insider Buying and Selling

In related news, Director Walter S. Woltosz sold 20,000 shares of the company's stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $27.66, for a total transaction of $553,200.00. Following the transaction, the director now owns 3,462,584 shares in the company, valued at $95,775,073.44. This represents a 0.57 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 19.40% of the stock is currently owned by corporate insiders.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.